関連する実験動画
Updated: Jul 13, 2026

04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
レウマチ性関節炎患者におけるメソトレキサートの効果,心血管関連合併症
Lancet (London, England)
|May 23, 2000
まとめ
リウマチ性関節炎の薬であるメソトレクサートは,ホモシステインのレベルを上昇させ,心血管疾患の患者の死亡リスクを高めます. これは,心疾患のリウマチ性関節炎患者の管理における重大な安全性に関する懸念を浮き彫りにしています.
科学分野:
- レウマトロジーの病理学
- 心血管医学 心血管医学
- 薬理学 薬理学とは
背景:
- リウマチ性関節炎 (RA) は慢性炎症性疾患である.
- メソトレクサートは一般的な抗レウマティック薬である.
- 心血管共同疾患は,RA患者の間で一般的です.
研究 の 目的:
- 心血管関連併発性のあるリウマチ性関節炎患者の死亡率に対するメトトレキサートの影響を調査する.
主な方法:
- 観察試験の設計. 観察試験のデザイン.
- 薬剤,併発症,死亡率を含む患者データの分析.
- リスク要因を特定するための統計分析.
主要な成果:
- メソトレクサート使用は死亡率の増加と関連していました.
- 血清ホモシステイン濃度の上昇は,寄与する要因である可能性があります.
- このリスクは,特に心血管合併症の患者で顕著でした.
結論:
- メソトレキサートは,心血管疾患を有するリウマチ性関節炎患者の死亡リスクを増やす可能性があります.
- これらの患者のホモシステインのレベルをモニタリングすることは重要です.
- メソトレキサート,ホモシステイン,および心血管疾患のアウトカムを結びつけるメカニズムに関するさらなる研究が必要である.
関連する概念動画
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation IV: Nursing Management
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
